Group 1 - The article discusses the recent IPO counseling registrations of eight companies, including Tengli Transmission, Fangyi Co., and Huasheng Radar, indicating a trend of companies preparing for public offerings in China [1] - Tengli Transmission, which previously withdrew its IPO application in July 2024, is now seeking to re-enter the market with a focus on automotive components [3][4] - Fangyi Co. has recently completed a targeted financing of 60 million yuan and is preparing for an IPO on the Beijing Stock Exchange [7][8] - Huasheng Radar, a specialized radar technology company, has secured significant investment and has reported a doubling of orders in the first half of 2024 compared to its 2023 revenue [12][13] - Honor is positioning itself to become the third publicly listed smartphone giant in China, following Xiaomi and Transsion Holdings, with its IPO application submitted in June 2025 [14][15][16] - Lansheng Biotechnology, a low-toxicity pesticide manufacturer, has also initiated its IPO counseling, with a current valuation of 1.752 billion yuan [18][19][21] - Peiyuan Co., a hidden champion in the automotive shock absorber sector, is facing revenue growth without corresponding profit increases, indicating potential operational challenges [22] - Ziguang Zhanrui is preparing for an IPO on the Sci-Tech Innovation Board, aiming to become the first publicly listed domestic smartphone chip company, with a post-investment valuation of approximately 70 billion yuan [24][26] Group 2 - Tengli Transmission's revenue has shown consistent growth from 2020 to 2023, with total revenues of 2.92 billion yuan, 3.77 billion yuan, 5.10 billion yuan, and 6.1 billion yuan respectively, indicating a strong upward trend [5] - Fangyi Co. reported revenues of 1.93 billion yuan, 2.05 billion yuan, and 2.53 billion yuan from 2022 to 2024, but its net profit has seen a decline, highlighting profitability issues despite revenue growth [11] - Huasheng Radar's revenue for 2023 was 2.4 billion yuan, with a significant increase in orders in 2024, suggesting strong market demand for its products [13] - Lansheng Biotechnology's financial data shows a net profit of 2.69 billion yuan for 2024, with a focus on developing green pesticides and holding 39 patents [19][21] - Peiyuan Co. reported revenues of 6.34 billion yuan and 6.72 billion yuan for 2023 and 2024, respectively, but faced a decline in net profit, indicating operational challenges [22] - Ziguang Zhanrui's revenue figures for 2022, 2023, and 2024 were 14 billion yuan, 13 billion yuan, and 14.5 billion yuan, respectively, but the company has yet to achieve profitability [26]

Group 1 - A total of 8 Hong Kong companies launched their IPOs on June 30, including companies from various sectors such as robotics, semiconductors, and biomedicine [1] - In the first half of 2025, Hong Kong welcomed 43 new IPOs, a 43.3% increase from 30 in the same period of 2024, with total funds raised amounting to approximately HKD 1,067.1 billion [2][4] - The top three IPOs by fundraising in the first half of 2025 were Ningde Times, Heng Rui Pharmaceutical, and Hai Tian Wei Ye, raising HKD 410.1 billion, HKD 113.7 billion, and HKD 101.3 billion respectively, accounting for 58.6% of the total IPO fundraising [7][8] Group 2 - The healthcare and consumer discretionary sectors had the highest number of new listings in 2025, with 10 and 8 companies respectively, while the industrial sector led in fundraising [9] - Among the 43 new IPOs, 27 companies saw their stock prices rise on the first day of trading, resulting in a first-day drop rate of 30.2% [9][10] - The most significant first-day price increases were recorded by Ying En Biotechnology-B and Yao Jie An Kang-B, with gains of 116.7% and 78.7% respectively [10][12] Group 3 - The IPO subscription rates were notably high, with several companies experiencing over 1,000 times subscription, including Bluco, which had a subscription rate of 6,000 times [13][14] - A total of 35 out of 43 companies triggered the allocation mechanism, indicating a higher success rate for companies that utilized this strategy [16] - As of June 30, 2025, there were 134 companies that received approval for overseas IPOs, with over 160 companies currently in the queue for Hong Kong IPOs [18]

Core Insights - The article highlights the significant investment of 3.4 billion yuan by Zhong Shanshan into Jinbo Biological, marking a record for the Beijing Stock Exchange's private placement [1][2] - This investment strategy combines private placement and agreement transfer, allowing Zhong to become the second-largest shareholder with a 10.58% stake in Jinbo Biological [2] Investment Strategy - Zhong Shanshan's investment is executed through two companies: Yangshengtang and Hangzhou Jiushi, with Yangshengtang subscribing to up to 2 billion yuan in shares and Hangzhou Jiushi acquiring 5% of shares for 1.403 billion yuan [2] - The dual approach of private placement and agreement transfer mitigates market pressure on stock prices while providing Jinbo Biological with essential funding for its core project [2] Market Potential - Jinbo Biological holds a unique position in the recombinant collagen market, being the only company to have industrialized Class III medical devices [3] - The company's medical device revenue is projected to account for 86.89% of its total income in 2024, with a gross margin of 95.03%, surpassing that of Guizhou Moutai [3] - The recombinant collagen market is expected to grow significantly, reaching 58.57 billion yuan by 2025 and potentially exceeding 219.3 billion yuan by 2030 [3] Strategic Synergy - The investment aligns with the strategic interests of Yangshengtang, which can leverage Jinbo Biological's technology in health-related products [4] - Jinbo Biological's high gross margin and growth potential provide new revenue opportunities for Yangshengtang, creating a comprehensive cycle of research, industrialization, and commercialization [4] Competitive Landscape - Despite Jinbo Biological's leading position, competition in the recombinant collagen sector is intensifying, with companies like Huaxi Biological and Juzhi Biological also entering the market [5] - The sustainability of Jinbo Biological's technological edge and the need for product diversification are critical challenges that both Jinbo Biological and Zhong Shanshan will face [5] Conclusion - Zhong Shanshan's investment is a strong endorsement of Jinbo Biological's technological capabilities and market potential, aiming to solidify its leadership in the recombinant collagen sector while enabling Yangshengtang to enter the high-end biomaterials market [6]

Core Insights - The number of unicorn companies globally has reached 1,523, with China accounting for 343 of them [1] - Among the Chinese unicorns, four companies from Changzhou made the list, three of which are in the new energy sector, while Chenrui Optics is the only optical company included [1] Company Overview - Chenrui Optics, a subsidiary of AAC Technologies, focuses on optical solutions and was established in 2008 [2][3] - The company has established long-term strategic partnerships with major smartphone brands and is one of the top three suppliers of optical lenses globally [2] Financial Performance - Chenrui Optics has experienced rapid growth since 2019, with revenue increasing from 1.07 billion RMB in 2019 to 5 billion RMB in 2024, representing a compound annual growth rate (CAGR) of over 36% [3] - The company's main products include optical lenses, camera modules, and WLG glass lenses, and it is one of the few companies in the industry that can provide a full-link solution [3] Product Development - The flagship product, WLG plastic-glass hybrid lens, is expected to achieve a shipment volume of ten million units this year, marking the large-scale production and application of this lens in flagship smartphone models [3] Market Context - The Hurun Research Institute's unicorn list includes non-public companies founded after 2000 with a valuation of over 1 billion USD, with the valuation cutoff date set for January 1, 2025 [3] - The report highlights that creating a company valued at 1 billion USD typically requires at least ten years of effort, emphasizing the long-term commitment behind such successes [3]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 细胞 （Cell） 作为生命的基本单位，是一个极其复杂精妙的实体，其特性和行为对物理和计算模型的极限构成了挑战。每个细胞都是一个动态且具有适应性的系 统，在其中，复杂的活动源自无数的分子间相互作用。为了理解细胞的功能， 科学家们试图构建 虚拟细胞 （ Virtual Cell ） 模型来模拟、预测和引导细胞的行 为。 如今，在 人工智能 和 组学 领域发生的令人振奋的科技革命，使得直接从数据中学习构建细胞模型成为可能。这些科技革命为一个雄心勃勃的 人工智能虚拟细胞 （AIVC） 愿景提供了前所未有的机遇，AIVC 是一种基于大规模神经网络的多尺度、多模态模型，能够表征和模拟分子、细胞和组织在各种状态下的行为。 目前，已有多个研究团队正在竞相开发 人工智能 （AI） 模型，以建模生命的基本单位—— 细胞 ，并预测细胞的行为。 2024 年 12 月 12 日， "陈-扎克伯格倡议" （CZI） 的科学负责人 Stephen Quake 联合 40 多位学者，在 Cell 期刊发表了题为： How to build the virtual cell with artific ...

将投中网设为"星标⭐"，第一时间收获最新推送 为两地科创生态注入持续动能。 来源丨 投中网 6月27日下午，上实集团创新发展暨人才工作会议在上海、香港两地同时举行。会议围绕"智创上 实，聚才领航"主题，集团公布在沪港两地的生命健康、环境健康、人才建设、智慧城市、未来产业 等领域的多项创新成果。 中国科学院院士陈凯先、上海交通大学校长丁奎岭、香港创新科技及工业局局长孙东教授、香港科技 园公司行政总裁黄克强、香港生物医药创新协会会长卢毓琳及香港大学新兴技术研究所讲座教授席宁 等来自沪港两地的政府机构、企业、科学家、高校学者、园区代表视频表示祝贺 ，肯定上实集团在 构建跨境合作生态、推动沪港协同创新的重要价值，期待未来上实集团持续发挥产业龙头引领作用， 深化沪港产业资源与科研优势融合，为两地科创生态注入持续动能。 上实集团始终视深化沪港联动为己任，积极搭建两地创新要素流通的桥梁，在推动香港创科产业方面 进行诸多尝试：已与香港科技大学联合发起专注香港及大湾区高校科研成果转化孵化的香港生物科技 基金；与香港大学及上海产研院共建未来智能科技孵化器，加速AI与机器人技术融合应用。同时， 深化与香港科技园公司合作，共同打造沪 ...

Core Insights - A significant breakthrough in bioprinting has been achieved by an international research team led by Wake Forest University, which successfully 3D printed functional human islets using a new type of bioink, offering new hope for the treatment of Type 1 diabetes [1] Group 1 - The research demonstrates substantial clinical application potential for the treatment of Type 1 diabetes [1] - The results were first presented at the 2025 European Society of Organ Transplantation Congress, highlighting its importance in the field of regenerative medicine [1]

一周IPO动态，覆盖港股、美股、A股。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 曹操出行 港股｜挂牌上市 据 IPO早知道消息，CaoCao Inc.（曹操出行有限公司，以下简称"曹操出行"）于2025年6月25日 正式以"2643"为股票代码在港交所主板挂牌上市。 成立于 2015年的曹操出行作为一家由吉利集团孵化的网约车平台，现已成为中国最大的网约车平台 之一。截至2024年12月31日，曹操出行的业务已覆盖136座城市，其中2024年新拓展85座城市。 2023年和2024年，曹操出行的总GTV分别为122亿元和170亿元，分别较2022年和2023年增长 37.5%和38.8%。根据弗若斯特沙利文的资料，按GTV计算，曹操出行过去三年均一直位列中国网 约车平台前三名，其中2024年的市场份额进一步提升至行业第二。 今年第一季度，曹操出行的总 GTV为48亿元，较2024年同期增加54.9%，订单量亦较2024年同期 增长51.8%。 值得注意的是，截至 2024年12月31日，曹操出行在31个城市拥有一支超过34,000辆定制车的车 队供其附属司机使用。根据弗若斯特沙 ...

据港交所文件，杭州德适生物科技股份有限公司向港交所提交上市申请书。 ...

Core Viewpoint - The integration of AI technology in interdisciplinary research, particularly in agricultural science, is leading to innovative breakthroughs, such as the development of efficient gene editing tools to enhance food security and support national strategic needs [1][2]. Group 1: AI and Interdisciplinary Research - Beijing Zhongguancun Academy focuses on AI and interdisciplinary education and research, collaborating with 31 universities to foster scientific exploration and technological advancements [1]. - The "AI + dry-wet loop" project aims to develop domestically-owned efficient micro gene editing tools to overcome foreign patent barriers and support molecular breeding for crop improvement [2]. Group 2: Gene Editing Technology - The project has reportedly increased the editing efficiency of specific gene editing tools by approximately three times, which could significantly shorten breeding cycles and enhance crop traits [3]. - The research targets enzymes involved in photosynthesis to improve efficiency and increase food production [2][3]. Group 3: Student Involvement and Perspectives - Students with AI academic backgrounds are actively participating in the project, motivated by the potential to contribute to national food security and the enthusiasm of their mentors [3][4]. - The project is seen as a dual application of gene editing technology in both agriculture and medical research, showcasing its broad potential [4]. Group 4: Institutional Support and Development - The development of Beijing Zhongguancun Academy is part of Beijing's broader initiative to integrate education, technology, and talent development [4][5]. - The Beijing Municipal Education Science and Technology Talent Working Group is responsible for coordinating efforts to support cutting-edge fields like gene editing technology [5].